Somatic CHEK2 in breast: minimal PARPi activity; standard subtype-directed therapy. ESCAT...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-CHEK2-SOMATIC-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | CHEK2 somatic loss-of-function |
| Disease | DIS-BREAST |
| ESCAT tier | IIIA |
| Recommended combinations | standard breast therapy by subtype |
| Contraindicated monotherapy | PARPi monotherapy |
| Evidence summary | Somatic CHEK2 in breast: minimal PARPi activity; standard subtype-directed therapy. ESCAT IIIA / OncoKB Level 4. |
Notes
Reflex germline testing recommended.
Used By
No reverse references found in the YAML corpus.